X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs IPCA LABS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH IPCA LABS PANACEA BIOTECH/
IPCA LABS
 
P/E (TTM) x 145.3 38.8 374.2% View Chart
P/BV x 3.2 3.0 108.4% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PANACEA BIOTECH   IPCA LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
IPCA LABS
Mar-17
PANACEA BIOTECH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs149643 23.1%   
Low Rs82503 16.4%   
Sales per share (Unadj.) Rs84.1254.4 33.1%  
Earnings per share (Unadj.) Rs-18.316.1 -113.9%  
Cash flow per share (Unadj.) Rs-6.729.8 -22.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7194.6 43.0%  
Shares outstanding (eoy) m61.25126.20 48.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.3 61.0%   
Avg P/E ratio x-6.335.7 -17.7%  
P/CF ratio (eoy) x-17.219.2 -89.6%  
Price / Book Value ratio x1.42.9 46.9%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m7,07472,300 9.8%   
No. of employees `0002.813.3 20.7%   
Total wages/salary Rs m1,4496,960 20.8%   
Avg. sales/employee Rs Th1,874.12,413.5 77.7%   
Avg. wages/employee Rs Th527.0523.2 100.7%   
Avg. net profit/employee Rs Th-407.7152.4 -267.5%   
INCOME DATA
Net Sales Rs m5,15432,106 16.1%  
Other income Rs m100226 44.2%   
Total revenues Rs m5,25432,332 16.2%   
Gross profit Rs m-7664,448 -17.2%  
Depreciation Rs m7111,730 41.1%   
Interest Rs m1,503241 624.2%   
Profit before tax Rs m-2,8812,703 -106.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17675 2.5%   
Profit after tax Rs m-1,1212,028 -55.3%  
Gross profit margin %-14.913.9 -107.3%  
Effective tax rate %-0.625.0 -2.3%   
Net profit margin %-21.86.3 -344.5%  
BALANCE SHEET DATA
Current assets Rs m3,81017,340 22.0%   
Current liabilities Rs m8,3659,559 87.5%   
Net working cap to sales %-88.424.2 -364.7%  
Current ratio x0.51.8 25.1%  
Inventory Days Days156100 155.2%  
Debtors Days Days6757 118.2%  
Net fixed assets Rs m14,48020,779 69.7%   
Share capital Rs m61252 24.3%   
"Free" reserves Rs m90324,499 3.7%   
Net worth Rs m5,12724,553 20.9%   
Long term debt Rs m5,8323,517 165.8%   
Total assets Rs m19,43339,595 49.1%  
Interest coverage x-0.912.2 -7.5%   
Debt to equity ratio x1.10.1 793.9%  
Sales to assets ratio x0.30.8 32.7%   
Return on assets %2.05.7 34.3%  
Return on equity %-21.98.3 -264.8%  
Return on capital %3.610.5 34.7%  
Exports to sales %24.548.6 50.4%   
Imports to sales %10.214.2 71.5%   
Exports (fob) Rs m1,26415,617 8.1%   
Imports (cif) Rs m5254,571 11.5%   
Fx inflow Rs m1,53915,617 9.9%   
Fx outflow Rs m9425,828 16.2%   
Net fx Rs m5979,790 6.1%   
CASH FLOW
From Operations Rs m5992,764 21.7%  
From Investments Rs m-438-1,432 30.6%  
From Financial Activity Rs m-303-1,591 19.0%  
Net Cashflow Rs m-141-259 54.6%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.4 5.3%  
FIIs % 1.3 25.3 5.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.4 135.6%  
Shareholders   10,259 36,892 27.8%  
Pledged promoter(s) holding % 35.1 2.1 1,638.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  CIPLA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 19, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS